Form 4: Director Nancy Thornberry Reports VRTX Equity Transactions

Vertex Pharmaceuticals director Nancy Thornberry reported the acquisition of restricted stock units, stock options, and a deferral of shares into deferred stock units.

Summary

• Director Nancy Thornberry acquired 472 restricted stock units (RSUs) on May 1, 2026.
• The director was granted 1,433 stock options with an exercise price of $424.45, which are fully vested.
• Upon the vesting of prior RSU grants, 398 shares were deferred into 398 deferred stock units (DSUs) under the company's deferred compensation plan.
• Following these transactions, the director's direct beneficial ownership stands at 2,109 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation and administrative share management rather than a strategic shift or market-moving event.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.
• The grant of stock options and RSUs reflects standard long-term incentive compensation for board members.

Negatives

• None identified; these are standard compensatory transactions for a board member.

Risks

• The value of the acquired stock options is subject to market volatility and the future performance of Vertex Pharmaceuticals common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity transactions.

Management Comments

• The transactions reflect standard board compensation and deferral elections under the company's existing deferred compensation plan.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of director compensation common in the biotechnology sector, where equity-based incentives are standard practice to ensure board alignment with long-term corporate strategy.

Comparison to Industry Standards

• The use of RSUs and stock options for board compensation is consistent with standard practices at large-cap pharmaceutical companies like Amgen, Gilead, and Regeneron.
• The deferral of vested shares into DSUs is a common tax and retirement planning strategy utilized by directors in the S&P 500.

Corporate Governance

Stakeholder Impact

• No material impact on shareholders, employees, or creditors as these are standard director equity transactions.

Next Steps

• The RSUs are scheduled to vest on the first anniversary of the grant date.
• The deferred stock units will be paid out upon the director's departure from the board, a change of control, or in the event of disability or death.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, Insider Trading, Director Compensation, Equity Grants